Genetic culprit in pancreatic cancer risk identified

Share this article:

Mutations in the ATM gene may raise a person's hereditary risk for pancreatic cancer, information that could lead to better screening methods for the disease, researchers have learned.

Approximately 10% of people with pancreatic cancer come from families with multiple cases of the disease. To confirm the suspicion that this clustering was genetically based, a team led by Alison Klein, PhD, director of the National Familial Pancreas Tumor Registry at The Johns Hopkins Hospital in Baltimore, Maryland, sought to identify ATM gene mutations in persons with and without pancreatic cancer.

Using whole genome and whole exome analyses, the researchers learned that 4 of 166 persons (2.4%) with pancreatic cancer had the ATM mutations, but 190 spousal control subsets did not. Among the 87 most severely affected families—those with three or more cases of pancreatic cancer—four mutations were found (4.6%).

Although the genes responsible for the majority of cases of familial pancreatic ductal adenocarcinoma remain unknown, “Our results indicate that inherited ATM mutations play an important role in familial pancreatic cancer predisposition” wrote Klein and colleagues in their report for Cancer Discovery (http://cancerdiscovery.aacrjournals.org/content/early/2011/12/23/2159-8290.CD-11-0194.full.pdf+html?sid=c4047f1c-af1d-437e-8a9b-0e98de86fe33). They also noted that the identification of these mutations has substantial implications for risk assessment and surveillance in family members of people with pancreatic cancer.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Landmark Medicare law had little impact on reducing chemotherapy cost

Legislation passed in 2003 intended to slow the spiraling costs of drugs paid for by the federal government to treat Medicare patients has not proved to be a success.

Follow-up colonoscopies too frequent and overused by endoscopists

A retrospective study has uncovered an overuse of colonoscopies for colorectal cancer screening and surveillance.

Current therapy for hypothyroidism endorsed by new guidelines

A recent review has found insufficient consistent data exist to recommend a change in use of levothyroxine as the only drug needed to treat hypothyroidism.